Last update June 28, 2021
Compatible
We do not have alternatives for Metronidazole (Dermal and Vaginal use) since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Metronidazole (Dermal and Vaginal use) is also known as
Metronidazole (Dermal and Vaginal use) belongs to these groups or families:
Main tradenames from several countries containing Metronidazole (Dermal and Vaginal use) in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | Vaginal: 20 | % |
Molecular weight | 171 | daltons |
Protein Binding | 20 | % |
VD | 0.5 - 1.1 | l/Kg |
pKa | 15.4 | - |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Metronidazole is used topically in the treatment of acne (Kong 2013) and vaginitis.
Metronidazole, when taken orally, is excreted in small amounts in breastmilk (van Wattum 2019, Geballa 2018, Zhang 1997, Passmore 1988, Heisterberg 1983, Erickson 1981, Gray 1961) and does not cause problems in infants (Passmore 1988, Gray 1961), and is considered compatible with breastfeeding.
The low content in topical preparations (<1% metronidazole) and its poor absorption through skin or vaginal mucosa makes it unlikely that it transfers to breastmilk in significant amounts.
Compared with oral administration, the plasma levels reached are 1% through the skin and 2% through the vagina (AEMPS 2018, Sanofi 2018, FDA 2005, AEMPS 2001) and is considered even more compatible with breastfeeding than via systemic administration (Rowe 2013, Kong 2013).
See below the information of this related product: